Condition: Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma · Sponsor: Universität des Saarlandes
The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the addition of Acalabrutinib. Participants will be randomised to receive either R-miniCHOP alone or R-miniCHOP with Acalabrutinib.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Saarland University Medical Center | Homburg, Saarland, Germany | Recruiting |
| MVZ am Klinikum Aschaffenburg | Aschaffenburg, Germany | Not Yet Recruiting |
| Helios Klinikum Emil von Behring | Berlin, Germany | Recruiting |
| Onkologische Schwerpunktpraxis Kurfürstendamm | Berlin, Germany | Not Yet Recruiting |
| Gemeinschaftspraxis Mohm/Prange-Krex | Dresden, Germany | Not Yet Recruiting |
| Universitätsklinikum Gießen und Marburg, Standort Gießen | Giessen, Germany | Recruiting |
| Universitätsmedizin Greifswald | Greifswald, Germany | Recruiting |
| Universitätsmedizin Halle (Saale) | Halle, Germany | Recruiting |
| Städtisches Klinikum Karlsruhe | Karlsruhe, Germany | Recruiting |
| Johannes Wesling Klinikum | Minden, Germany | Not Yet Recruiting |
| Rheinland Klinikum-Lukaskrankenhaus Neuss | Neuss, Germany | Not Yet Recruiting |
| Brüderkrankenhaus St. Josef | Paderborn, Germany | Not Yet Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05820841